RxDoctor Payments Data

Pradeep Kamboj, MD

Family Medicine · Tulare, CANPI 1720178601

Payments from drug & device makers

$11,376in general payments, 2019–2025

Across 564 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • GSK$992
  • AbbVie$918
  • Boehringer Ingelheim$753
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$11,358100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,376 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$199,201
Medicare patients
384
Services billed
3,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$205,864
Trelegy ElliptaFluticasone/Umeclidin/Vilanter157$165,560
EliquisApixaban115$110,697
MounjaroTirzepatide52$56,384
JardianceEmpagliflozin42$51,064
JanuviaSitagliptin Phosphate29$37,353
FarxigaDapagliflozin Propanediol32$34,305
MyrbetriqMirabegron36$32,440
LinzessLinaclotide44$32,216
Breo ElliptaFluticasone/Vilanterol51$32,100
Bydureon BciseExenatide Microspheres19$23,037
Spiriva RespimatTiotropium Bromide24$22,472
Tresiba Flextouch U-200Insulin Degludec24$22,455
XareltoRivaroxaban16$18,715
Wixela InhubFluticasone Propion/Salmeterol100$14,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$426$205,864152 claims
GSKTrelegy Ellipta, Breo Ellipta$992$197,661208 claims
PfizerEliquis, Nurtec Odt, Premarin$594$130,380145 claims
Boehringer IngelheimJardiance, Spiriva Respimat$753$73,53666 claims
Lilly USA, LLCMounjaro$1,031$56,38452 claims
AstraZenecaFarxiga, Symbicort$2,014$46,61557 claims
MerckJanuvia$595$37,35329 claims
Astellas Pharma US IncMyrbetriq$32$32,44036 claims
AbbVieLinzess$918$32,21644 claims
Johnson & JohnsonXarelto$31$18,71516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Tulare

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →